A Fusun Kalpaklioglu1, Ilkay K Kalkan. 1. Department of Immunology and Allergic Diseases, Faculty of Medicine, Kirikkale University, Kirikkale, Turkey. afusunk@yahoo.com
Abstract
BACKGROUND: Fractional exhaled nitric oxide (FeNO), a well-known marker of airway inflammation, is rarely evaluated in rhinitis of different etiology. We aimed to compare the eNO levels in allergic rhinitis (AR) and nonallergic rhinitis (NAR) with/without asthma, as well as the contributing factors that interfere with elevated FeNO. METHODS: Patients were enrolled based on chronic nasal symptoms. Orally exhaled NO was measured with the single exhalation method at 50 mL/s. All subjects underwent a panel of tests: skin-prick tests, asthma control test, blood sampling, spirometry, and health-related quality-of-life questionnaires. RESULTS: The study group consisted of mainly women (130 women/41 men), with a mean age of 32.6 ± 13.2 years. AR was diagnosed in 122 (78.2%), NAR in 34 (21.8%), and 15 subjects were healthy controls. FeNO was insignificantly higher in patients with AR compared with patients with NAR and controls (32.2 parts per billion [ppb] versus 27 and 19.4 ppb), with no difference between genders. NAR + asthma had higher FeNO than those without asthma (40.5 ppb versus 14.9 ppb; p < 0.03), whereas accompanying asthma did not affect FeNO levels in the AR group. AR ± asthma had significantly higher FeNO levels than the NAR-only group (p < 0.01). Among AR + asthma, perennial sensitization caused higher FeNO levels than did seasonal allergens (48.5 ± 33.9 and 19.5 ± 13.6' p = 0.003), whereas FeNO was significantly higher during the allergen season. Nasally inhaled corticosteroids insignificantly reduced FeNO levels in all groups. Severity and seasonality of rhinitis, asthma, and ocular symptoms, but not gender, age, body mass index, Total IgE, forced expiratory volume in 1 second, and smoking, were associated with FeNO. CONCLUSION: Rhinitis and comorbid asthma are responsible for increased FeNO, irrespective of atopy. However, NAR without asthma may not be considered as a strong risk factor for airway inflammation.
BACKGROUND: Fractional exhaled nitric oxide (FeNO), a well-known marker of airway inflammation, is rarely evaluated in rhinitis of different etiology. We aimed to compare the eNO levels in allergic rhinitis (AR) and nonallergic rhinitis (NAR) with/without asthma, as well as the contributing factors that interfere with elevated FeNO. METHODS:Patients were enrolled based on chronic nasal symptoms. Orally exhaled NO was measured with the single exhalation method at 50 mL/s. All subjects underwent a panel of tests: skin-prick tests, asthma control test, blood sampling, spirometry, and health-related quality-of-life questionnaires. RESULTS: The study group consisted of mainly women (130 women/41 men), with a mean age of 32.6 ± 13.2 years. AR was diagnosed in 122 (78.2%), NAR in 34 (21.8%), and 15 subjects were healthy controls. FeNO was insignificantly higher in patients with AR compared with patients with NAR and controls (32.2 parts per billion [ppb] versus 27 and 19.4 ppb), with no difference between genders. NAR + asthma had higher FeNO than those without asthma (40.5 ppb versus 14.9 ppb; p < 0.03), whereas accompanying asthma did not affect FeNO levels in the AR group. AR ± asthma had significantly higher FeNO levels than the NAR-only group (p < 0.01). Among AR + asthma, perennial sensitization caused higher FeNO levels than did seasonal allergens (48.5 ± 33.9 and 19.5 ± 13.6' p = 0.003), whereas FeNO was significantly higher during the allergen season. Nasally inhaled corticosteroids insignificantly reduced FeNO levels in all groups. Severity and seasonality of rhinitis, asthma, and ocular symptoms, but not gender, age, body mass index, Total IgE, forced expiratory volume in 1 second, and smoking, were associated with FeNO. CONCLUSION:Rhinitis and comorbid asthma are responsible for increased FeNO, irrespective of atopy. However, NAR without asthma may not be considered as a strong risk factor for airway inflammation.
Authors: Justin Travers; Suzanne Marsh; Sarah Aldington; Mathew Williams; Philippa Shirtcliffe; Alison Pritchard; Mark Weatherall; Richard Beasley Journal: Am J Respir Crit Care Med Date: 2007-05-03 Impact factor: 21.405
Authors: Mario Olivieri; Giorgio Talamini; Massimo Corradi; Luigi Perbellini; Antonio Mutti; Claudio Tantucci; Mario Malerba Journal: Respir Res Date: 2006-06-30
Authors: Mohamed A Gashouta; Christian A Merlo; Matthew R Pipeling; John F McDyer; J W Awori Hayanga; Jonathan B Orens; Reda E Girgis Journal: J Heart Lung Transplant Date: 2014-11-06 Impact factor: 10.247
Authors: Dennis J Shusterman; Barak M Spector; Andrew N Goldberg; Edward M Weaver; Bradley A Otto; Kai Zhao Journal: Int Forum Allergy Rhinol Date: 2021-12-18 Impact factor: 5.426
Authors: Yue Zhang; Kiros Berhane; Sandrah P Eckel; Muhammad T Salam; William S Linn; Edward B Rappaport; Theresa M Bastain; Frank D Gilliland Journal: PLoS One Date: 2015-07-27 Impact factor: 3.240